KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Accumulated Depreciation & Amortization: 2015-2025

Historic Accumulated Depreciation & Amortization for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to $37.3 million.

  • BeOne Medicines' Accumulated Depreciation & Amortization fell 47.70% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.9 million, marking a year-over-year increase of 7.30%. This contributed to the annual value of $171.8 million for FY2024, which is 95.91% up from last year.
  • Per BeOne Medicines' latest filing, its Accumulated Depreciation & Amortization stood at $37.3 million for Q3 2025, which was up 4.69% from $35.6 million recorded in Q2 2025.
  • BeOne Medicines' Accumulated Depreciation & Amortization's 5-year high stood at $71.3 million during Q3 2024, with a 5-year trough of $9.6 million in Q1 2021.
  • Its 3-year average for Accumulated Depreciation & Amortization is $33.2 million, with a median of $25.3 million in 2024.
  • As far as peak fluctuations go, BeOne Medicines' Accumulated Depreciation & Amortization spiked by 231.44% in 2024, and later tumbled by 47.70% in 2025.
  • BeOne Medicines' Accumulated Depreciation & Amortization (Quarterly) stood at $13.1 million in 2021, then surged by 37.31% to $18.0 million in 2022, then spiked by 32.21% to $23.8 million in 2023, then skyrocketed by 110.95% to $50.2 million in 2024, then slumped by 47.70% to $37.3 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $37.3 million for Q3 2025, versus $35.6 million for Q2 2025 and $32.8 million for Q1 2025.